Ronald Knickerbocker

Corporate Officer/Principal bei THESEUS PHARMACEUTICALS, INC.

58 Jahre

Health Technology

Consumer Services

Aktive Positionen von Ronald Knickerbocker

Unternehmen	Position	Beginn	Ende
THESEUS PHARMACEUTICALS, INC.	Corporate Officer/Principal	-	-

Unternehmen	Position	Beginn	Ende
Genzyme Corp. Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.	Corporate Officer/Principal	01.01.2004	01.01.2012
PFIZER, INC.	Corporate Officer/Principal	01.01.1999	01.01.2004
ANCHIANO THERAPEUTICS LTD.	Corporate Officer/Principal	07.03.2018	-

Texas A&M University

Doctorate Degree

International

Vereinigte Staaten

Operativ

Corporate Officer/Principal	4
Doctorate Degree	1
Graduate Degree	1

Sektoral

Health Technology	5
Consumer Services	2

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	1
PFIZER, INC.	Health Technology

Private Unternehmen	3
Anchiano Therapeutics Ltd. Anchiano Therapeutics Ltd. BiotechnologyHealth Technology Anchiano Therapeutics Ltd. is a clinical-stage biopharmaceutical company, which engages in tin the discovery, development and commercialization of drugs for cancer-related diseases. Its products include two drugs for cancer BC-819 and BC-821. The company was founded by Avraham Hochberg in 2004 and is headquartered in Jerusalem, Israel.	Health Technology
Genzyme Corp. Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.	Health Technology
Theseus Pharmaceuticals, Inc. Theseus Pharmaceuticals, Inc. BiotechnologyHealth Technology Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. It focuses on the discovery, development and commercialization of transformative targeted therapies. The company was founded by William C. Shakespeare, David C. Dalgarno, Iain D. Dukes, Wei Sheng Huang and Victor M. Rivera on December 29, 2017 and is headquartered in Cambridge, MA.	Health Technology